metformin has been researched along with Anaplasia in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Anaplasia: Loss of structural differentiation and useful function of neoplastic cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is a widely used drug to treat patients with type II diabetes." | 5.43 | Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016) |
| "Metformin is a widely used drug to treat patients with type II diabetes." | 1.43 | Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, J | 1 |
| Kim, WG | 1 |
| Zhao, L | 1 |
| Enomoto, K | 1 |
| Willingham, M | 1 |
| Cheng, SY | 1 |
1 other study available for metformin and Anaplasia
| Article | Year |
|---|---|
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model.
Topics: Adenocarcinoma, Follicular; Anaplasia; Animals; Antineoplastic Agents; Cell Proliferation; Diet, Hig | 2016 |